CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
2024 · New England Journal of Medicine · 101 citations
https://doi.org/10.1056/nejmoa2412309
L
Liron Walsh
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
35
Papers
2.1K
Citations
17
h-index
23
i10-index
Liron Walsh is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Renal Diseases and Glomerulopathies & Neurotransmitter Receptor Influence on Behavior & Parathyroid Disorders and Treatments. The author has an h-index of 17, co-authored 30 publications.
Papers by this author
worksSafety and efficacy of non-steroidal anti-inflammatory drugs to reduce ileus after colorectal surgery
2019 · British journal of surgery · 59 citations
https://doi.org/10.1002/bjs.11326
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease
2017 · Orphanet Journal of Rare Diseases · 37 citations
https://doi.org/10.1186/s13023-017-0693-2
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
2025 · New England Journal of Medicine · 9 citations
https://doi.org/10.1056/nejmoa2510209
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat